Abstract: The apparatus converts ethylene in a dilute ethylene stream and dilute benzene in an aromatic containing stream via alkylation to heavier hydrocarbons. The catalyst may be a zeolite such as UZM-8. The catalyst is resistant to feed impurities such as hydrogen sulfide, carbon oxides, and hydrogen and selectively converts benzene. At least 40 wt-% of the ethylene in the dilute ethylene stream and at least 20 wt-% of the benzene in the dilute benzene stream can be converted to heavier hydrocarbons.

Abstract: Plants and method of treating a combustion gas are presented in which NOx compounds are removed from the combustion gas to a predetermined level to thereby create a pre-cleaned combustion gas from which CO2 is removed in an absorber using an amine solvent. Preferably, the predetermined level of NOx compounds reduces nitro-amines, especially nitrosamine emission from the absorber to quantities of equal or less than 100 ppb.

Abstract: A solvent based flue gas processing system for removing CO2 from a flue gas stream is described. A catalyst is provided to increase the efficiency of the solvent in capturing CO2 from the flue gas stream or in regenerating the solvent.

Abstract: This invention relates to crystalline boehmitic aluminas the crystallites of which exhibit unusual dimensional differences in the space directions 020 and 120. This invention further relates to a method for preparing such aluminas and the follow-up products obtained therefrom by calcination.

Abstract: Spherical boron nitride nanoparticles having an average particle diameter of less than 50 nm is obtained by a method of synthesizing spherical boron nitride nanoparticles including the following steps; heating a mixture of boric acid ester and nitrogen gas in ammonia gas and argon gas to form reaction product; crystallizing reaction product to form precursor of spherical boron nitride nanoparticles; and, heating the precursor in inert gas.

Abstract: A unit for use within a furnace chamber having a gaseous environment of air, for carrying out a synthesizing process for synthesizing precursors to form a synthesized product at elevated temperatures. The materials of the synthesizing process are separated from the air of the furnace chamber by the vessel or the reductive material.

Abstract: The invention concerns calcium phosphates in granular form having an x-ray diffraction pattern characteristic of hydroxyapatite and good compressibility and flow properties in direct compression applications. The invention also concerns the method for preparing said granules characterized in that it comprises processing a suspension of brushite dicalcium phosphate having a certain particle-size distribution using a basic solution, and maintaining the pH at not less than 7.0 for a sufficient time interval to enable the transformation of the brushite calcium phosphate into hydroxyapatite calcium phosphate.

Abstract: A novel method for high quality crystal growth of intermetallic clathrates is presented. The synthesis of high quality pure phase crystals has been complicated by the simultaneous formation of both clathrate type-I and clathrate type-II structures. It was found that selective, phase pure, single-crystal growth of type-I and type-II clathrates can be achieved by maintaining sufficient partial pressure of a chemical constituent during slow, controlled deprivation of the chemical constituent from the primary reactant. The chemical constituent is slowly removed from the primary reactant by the reaction of the chemical constituent vapor with a secondary reactant, spatially separated from the primary reactant, in a closed volume under uniaxial pressure and heat to form the single phase pure crystals.

Abstract: The present disclosure relates to a method for making a carbon nanotube carbon nanotube structure. The method includes steps of providing a tubular carbon nanotube array; and drawing out a carbon nanotube structure from the tubular carbon nanotube array by using a drawing tool. The carbon nanotube structure is a carbon nanotube film or a carbon nanotube wire.

Abstract: Methods and apparatus for controlling a catalytic layer deposition process are provided. A feed stream comprising a carbon source is provided to a catalyst layer. An asymmetrical alternating current is applied to the catalyst layer. A polarization impedance of the catalyst layer is monitored. The polarization impedance can be controlled by varying the asymmetrical alternating current. The controlling of the polarization impedance provides control over the structure and amount of carbon particles deposited on the catalyst layer. The carbon particles may be in the form of nanotubes, fullerenes, and/or nanoparticles.

Abstract: Disclosed herein is a carbonized cellulose material having a graphite nanosized surface layer directly carbonized from a cellulose fiber, and a method of synthesizing a carbonized cellulose material having a graphite nanolayer on a surface thereof, including: i) heating a cellulose fiber in a reactor; ii) forming a primary carbonized cellulose while maintaining temperature of the reactor; iii) cooling the formed primary carbonized cellulose; iv) heating the cooled primary carbonized cellulose; v) forming a secondary carbonized cellulose while maintaining temperature of the reactor; vi) cooling the formed secondary carbonized cellulose.

Abstract: The present invention relates to synthesis of copper zinc tin sulfide, Cu2ZnSnS4, and its corresponding selenide and telluride analogs in ionic liquids. Cu2ZnSnS4 and related compounds are useful as absorber materials in thin film solar cells.

Abstract: The invention relates to a process for preparing hydrogen. According to the invention, monosilane or polysilane is converted to hydrogen at an elevated temperature with steam or oxygen.

Abstract: New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.

Abstract: Use of Mycobacterium bovis BCG killed by Extended Freeze Drying (EFD) for preventing or treating atherosclerosis.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia.

Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.

Abstract: In situ foamable dental bleaching compositions include a dental bleaching agent, thickening agent, polyol, and in situ foaming agent. The foamable dental bleaching compositions are initially dispensed as a dental bleaching gel. Upon placement of the dental bleaching gel onto a person's tooth surfaces, the in situ foaming agent causes the bleaching gel to foam. Dental bleaching systems include an in situ foamable dental bleaching composition within a pressurized container (e.g., bag-on valve container) having a nozzle that, when actuated, expels the in situ dental bleaching composition as a gel. Dental bleaching methods include dispensing the in situ foamable dental bleaching composition as a gel, contacting a person's tooth surfaces with the dental bleaching gel, and allowing the gel to expand and foam in order to dynamically distribute and replenish the dental bleaching agent to the tooth surfaces and into the interproximal spaces between teeth.

Abstract: The invention provides sunless tanning compositions for application to skin comprising an effective amount of at least one dopamine precursor, an effective amount of curcumin and a dermatologically acceptable carrier. Methods for preparation of said compositions are disclosed. When applied to the skin, the compositions may be used darken skin.

Abstract: Substituted benzylidene 2,4-pentanediones are found to provide stabilization to otherwise photosensitive compounds and compositions.

Abstract: Topical compositions are provided in which active compounds for topical delivery through the stratum corneum are complexed with nanospheres of a triblock copolymer having an A-B-A structure wherein each A end block is a water-soluble, hydrophilic and non-toxic polymer or oligomer; and the hydrophobic middle B block is a hydrophobic polymer or oligomer with the same or different repeating units having the structure according to formula:(I) wherein X is —C—R—C— or —C—; Z is between 2 and about 100, inclusive; R1 is CH?CH or (CH2), wherein n is from 0 to 18, inclusive; R2 is selected from hydrogen and straight and branched alkyl, alkoxy, alkylaryl and alkoxyaryl groups containing up to 18 carbon atoms; and R is selected from a bond or straight and branched alkyl, alkoxy, alkylaryl and alkoxyaryl groups containing up to 18 carbon atoms.

Abstract: The present invention includes a hair straightening formulation consisting of a hair fixative that will straighten the hair for at least 2-3 months after one application despite frequent washings of the hair as well as methods for obtaining said formulation. The formulation comprises as active ingredients one or more keratin hydrolysates and an aldehyde. Hair straightening system comprising shampoo and one or more conditioners are also provided. The invention is further directed to a method for straightening hair using said formulation.

Abstract: A blood vessel metal stent coating of amidoglucosan polysaccharide loaded with antibody comprises carrier material composed of chitosan and inartificial degradable acidic amidoglucosan polysaccharide and the effective dose of CD133 antibody loaded in the carrier material. The blood vessel metal stent coating is manufactured with self-assemble method to fix the CD133 antibody in the carrier material of the coating. The coating has good biocompatibility, water retention property, flexibility, flush resistance and bio-stability, and can specifically capture the vascular endothelial progenitor cells in human peripheral blood, and differentiate into vascular endothelial cells. The process would accelerate endothelialization to repair injured vessel caused and prevent restenosis and thrombosis efficiently.

Abstract: This invention deals with a carboxyl-bearing, amphiphilic, solid copolyester stent coating composition for multifaceted prevention of vascular restenosis through a plurality of physicopharmacological modes. The composition includes one or more bioactive compounds and a copolymerization product of polyalkylene glycol, end-grafted with one or more cyclic monomer and treated further to introduce carboxyl-bearing end- or side-groups. The invention also deals with bioactive agents in an ionically conjugated form. The present coating may be applied to a metallic or an absorbable polymeric stent for use in preventing vascular restenosis.

Abstract: The present invention is related to bait which is water resistance, especially for fire ants. Its water resistance, anti-oxidation and the use of fire ants favorite eating formula which can mix with different toxic substances, and the production is easy and low cost, suitable for use in Taiwan or other humid areas to control fire ants.

Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is a molecule capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), or systemic onset juvenile idiopathic arthritis (Still's Disease).

Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

Abstract: A bioengineering, in particular to develop novel probiotic preparations based on Bacillus-strain bacteria, which can be used for preventing and treating infectious diseases and disbiosis of a human being, farm animals and birds. The novel strains of B. subtilis 07 (VKPM No. B-8611) and B. licheniformis 09 (VKPM No. B-8610) exhibit a broad spectrum of antagonistic activity, high proteolytic and amylase activity and a distinct ability in terms of a lysozim production. Such strains do not compete with each other but enter into synergistic relations in the form of an increased antagonistic action of the biopreparation. The inventive biopreparation comprises the B. subtilis 07 VKPM No. B-8611 and B. licheniformis 09 VKPM No. B-8610 strains and a protective medium. Such biopreparation can also contain a solvent and/or filler and exhibits an increased antagonistic activity with respect to a wide range of pathogenic and opportunistic pathogenic microorganisms and a resistance to quite a number of antibiotics.

Abstract: The present invention is a superporous hydrogel with cells encapsulated within the hydrogel matrix, and a method for producing the same.

Abstract: Photosensitizer mixtures and method of treating cellulites by light illumination are presented. Photosensitizer is combined with cellular products, e.g. adipose cells, collagen, previously removed by liposuction. Concentrations used depend on treatment area, cellulite stage and whether cellulites are in depressed or elevated skin areas. The cosmetic treatment reduces/removes localized lipodystrophies, flaccidity, cellulite using localized laser, LED, etc emissions. Applied light energy destroys “fat” cells by a combination of chemical reactions primarily, and temperature, wherein cell walls break releasing cell fluid. Transmission devices guide radiation to the treatment site. One or more light sources like laser diodes or LEDs may be coupled into one or more optical fibers to increase the covered area and increase the amount of radiation in that area. Optical fibers can be introduced percutaneously or interstitially. Cell fluid in the treatment area is removed by a combination of techniques.

Abstract: Consumption of blue-green algae, or extracts thereof, enhances trafficking or homing of stem cells in animals by inducing a transient increase in the population of stem cells present in the animal's circulatory system. The animal may be healthy or suffering some disease or physiological condition.

Abstract: The present invention provides a method for effectively and reproducibly infecting canines with Leishmania infantum using sand flies to vector the parasite. The inventive method comprises several steps, including ensuring canines are naïve to Leishmania, infecting the canines using bites of Leishmania-infected sand fly bites, and evaluating successful transmission of the Leishmania parasites.

Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.

Abstract: The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10.

Abstract: This invention relates to compositions comprising a bacterium of the genus Dietzia that is useful for treating paratuberculosis in ruminants and to a method for culturing the bacterium. The invention further relates to methods of treating Johne's disease by administering to a mammal a composition of the invention.

Abstract: The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression Toll-like Receptor 4 mediated activation of the immune system. The invention further provides screening assays to identify compounds which have utility in the foregoing compositions and methods.

Abstract: The present invention relates to compositions containing IgG and methods for the promotion of nerve regeneration or prevention or inhibition of neuronal degeneration by IgG to ameliorate the effects of injury, disorder or disease of the nervous system.

Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for ?-1,6-glucan.

Abstract: Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.

Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.

Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.

Abstract: Compositions for treating neurodegenerative or amyloidogenic disorders such as Alzheimer's disease (AD) are provided. More particularly, anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.

Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.

Abstract: The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4+ T cell lineage with unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a basis for understanding the developmental pathway of Th-17 cells and offer novel avenues to modulate (stimulate or inhibit) this developmental program and offer new methods for the treatment and prevention of disease states and conditions related to aberrant activity of Th-17 cells.

Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

Abstract: The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.

Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.